Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Weill Cornell Medical College in Qatar
Doha, QatarPublikationen in Zusammenarbeit mit Forschern von Weill Cornell Medical College in Qatar (24)
2024
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
-
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Annals of Oncology
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
2021
-
Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial
Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027
-
The importance of low-dose CT screening to identify emphysema in asymptomatic participants with and without a prior diagnosis of COPD
Clinical Imaging, Vol. 78, pp. 136-141
2020
-
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1
-
Key components of a hepatobiliary surgery curriculum for general surgery residents: results of the FULCRUM International Delphi consensus
HPB, Vol. 22, Núm. 10, pp. 1429-1441
2019
-
Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis
Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673
-
Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse
Cancers, Vol. 11, Núm. 5
2018
-
Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Annals of Oncology, Vol. 29, Núm. 2, pp. 405-417
2017
-
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
British Journal of Haematology, Vol. 177, Núm. 3, pp. 404-413
-
European society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery
International Journal of Gynecological Cancer, Vol. 27, Núm. 7, pp. 1534-1542
-
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
Leukemia, Vol. 31, Núm. 11, pp. 2443-2448
2016
-
European society of gynaecologic oncology quality indicators for advanced ovarian cancer surgery
International Journal of Gynecological Cancer, Vol. 26, Núm. 7, pp. 1354-1363
-
Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma
Journal of Clinical Oncology, Vol. 34, Núm. 32, pp. 3921-3930
-
Impact of surgery for stage IA non-smallcell lung cancer on patient quality of life
Journal of Community and Supportive Oncology, Vol. 14, Núm. 1, pp. 37-44
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152
-
Recurrent venous thromboembolism in anticoagulated patients with cancer: Management and short-term prognosis
Journal of Thrombosis and Haemostasis, Vol. 13, Núm. 6, pp. 1010-1018
2014
-
Classification of current anticancer immunotherapies
Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508